3billion to Showcase Newborn Genomic Screening Service ‘3B-NEO’ at SSIEM 2026

• SSIEM 2026 to spotlight the latest research and clinical advances under the theme “Next Generation Metabolic Medicine”
• 3billion to present its WES-based rare disease diagnostic service and newborn genomic screening service, 3B-NEO
• Company aims to expand its global healthcare network and explore new business opportunities

SEOUL, South Korea, August 24, 2026 — 3billion, an AI-powered rare disease diagnostics company, announced that it will participate in SSIEM 2026, taking place August 25–28 in Helsinki, Finland.

At the symposium, 3billion will showcase its whole-exome sequencing (WES)-based rare disease diagnostic service and 3B-NEO, its genomic newborn screening (gNBS) service. The company aims to strengthen its global network and explore new business opportunities through discussions with rare disease experts and healthcare institutions.

The Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) is a major international symposium in the field of inherited metabolic disorders, bringing together experts to share the latest research and clinical advances in diagnosis and treatment. Under this year’s theme, “Next Generation Metabolic Medicine,” the symposium will highlight recent developments in the diagnosis and treatment of inherited metabolic disorders, newborn screening, and related fields.

The symposium will bring together major pharmaceutical, biotechnology, and rare disease companies, including 3billion, Moderna, Takeda, Sanofi, and CENTOGENE. Leading researchers and clinicians, including experts from the U.S. National Institutes of Health (NIH) Undiagnosed Diseases Network (UDN), are also expected to attend and share recent advances in rare disease diagnosis and treatment.

This year, 3billion launched 3B-NEO and Family Insight, a family-based genetic testing service, as part of its efforts to expand its services into prevention and early detection. This is particularly important for inherited metabolic disorders, some of which can progress rapidly even when no obvious symptoms are present at birth. In response to this need, 3B-NEO analyzes 704 genes associated with serious genetic disorders, including metabolic, immunological, and neuromuscular conditions, supporting timely follow-up and clinical management.

“Early detection and timely management can have a meaningful impact on outcomes for patients with inherited metabolic disorders,” said Changwon Keum, CEO of 3billion. “At SSIEM 2026, we look forward to presenting our genetic diagnostic capabilities and 3B-NEO to rare disease experts from around the world and expanding opportunities for collaboration.”